Bayer's Pipeline Gains Are Real, but the Profit Test Comes on November 3

Bayer investors are being asked to hold two ideas in their heads at once: the drug pipeline is moving, and the near-term earnings picture is not necessarily moving with it. A clutch of regulatory and clinical updates over the past fortnight has reinforced the longer-term development story, while the sell side is quietly trimming its expectations for what the company will actually earn when it reports.

Start with what has been achieved and what has not. Roughly a week ago, the US Food and Drug Administration accepted Bayer's supplemental application for finerenone — sold as Kerendia — in chronic kidney disease without diabetes. The filing rests on positive Phase III data from the FIND-CKD trial, so there is study evidence behind the requested label expansion. Acceptance, though, is a procedural step, not an approval, and the distinction matters for anyone reading the news as a de-risking event.

Two projects, two very different stages of maturity

A separate announcement from Vividion Therapeutics, a wholly owned Bayer subsidiary, illustrates the same point from the opposite direction. The company dosed its first patient in a global Phase II study of the oral WRN inhibitor VVD-214 in combination with pembrolizumab, testing it in previously untreated advanced colorectal cancer with MSI-H or dMMR status. Here the emphasis is clinical investigation rather than regulatory review. Both items feed the pipeline, but they cannot be judged as projects of equal maturity — one is awaiting a verdict on existing data, the other is still gathering it.

The analysts are not reading from the same page on profits

JPMorgan's Richard Vosser reaffirmed an Overweight rating on the stock yesterday with a price target of 61 euros, against a Friday close of €44.19. His optimism comes with a caveat that speaks directly to the upcoming results: he sees revenue running 2% above consensus, but expects EBITDA 6% below it, while looking for the full-year guidance to be confirmed. That combination — a top-line beat paired with a softer operating result — is entirely compatible with a reiterated outlook, and it is the number that will matter when the quarter lands.

UBS took a more straightforwardly constructive line on Wednesday, keeping Bayer at Buy with a target of 62 euros. Analyst Matthew Weston attributed the weakness in the agricultural business to already-known causes and described the trends for 2026/2027 as intact. His view rests on two assumptions rather than reported figures: that the crop science drag will not alter the broader picture, and that pharma momentum has continued. Weston also flagged the US approval of asundexian as a key item on his radar.

Capital spending adds a third thread

Beyond the pill bottle, Bayer has committed $2.2 billion to a new pharmaceutical production site in New Albany, Ohio, with around 600 jobs planned — an announcement made roughly two weeks ago. Like the pipeline news, it is a statement of intent rather than a line in the income statement, and it sits alongside the near-term earnings question rather than answering it.

November 3 is the date that settles the argument

Bayer publishes third-quarter 2026 results on November 3. That is when investors can check whether the split JPMorgan describes — stronger sales, weaker EBITDA — actually materialises, and whether the annual guidance holds. Until then, the development headlines carry the narrative. What they cannot do is substitute for revenue, operating profit and the outlook. The real question is not simply whether projects are advancing, but how far each has genuinely travelled.